JP2022552008A5 - - Google Patents

Info

Publication number
JP2022552008A5
JP2022552008A5 JP2022523023A JP2022523023A JP2022552008A5 JP 2022552008 A5 JP2022552008 A5 JP 2022552008A5 JP 2022523023 A JP2022523023 A JP 2022523023A JP 2022523023 A JP2022523023 A JP 2022523023A JP 2022552008 A5 JP2022552008 A5 JP 2022552008A5
Authority
JP
Japan
Prior art keywords
lnp
substituted
composition
tissue
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022523023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552008A (ja
JP7744687B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056255 external-priority patent/WO2021077067A1/en
Publication of JP2022552008A publication Critical patent/JP2022552008A/ja
Publication of JP2022552008A5 publication Critical patent/JP2022552008A5/ja
Priority to JP2025147778A priority Critical patent/JP2025175052A/ja
Application granted granted Critical
Publication of JP7744687B2 publication Critical patent/JP7744687B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022523023A 2019-10-18 2020-10-19 CAR mRNA送達のための脂質ナノ粒子とその製剤 Active JP7744687B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025147778A JP2025175052A (ja) 2019-10-18 2025-09-05 CAR mRNA送達のための脂質ナノ粒子とその製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916942P 2019-10-18 2019-10-18
US62/916,942 2019-10-18
PCT/US2020/056255 WO2021077067A1 (en) 2019-10-18 2020-10-19 Lipid nanoparticles and formulations thereof for car mrna delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025147778A Division JP2025175052A (ja) 2019-10-18 2025-09-05 CAR mRNA送達のための脂質ナノ粒子とその製剤

Publications (3)

Publication Number Publication Date
JP2022552008A JP2022552008A (ja) 2022-12-14
JP2022552008A5 true JP2022552008A5 (cg-RX-API-DMAC7.html) 2023-10-25
JP7744687B2 JP7744687B2 (ja) 2025-09-26

Family

ID=75538674

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523023A Active JP7744687B2 (ja) 2019-10-18 2020-10-19 CAR mRNA送達のための脂質ナノ粒子とその製剤
JP2025147778A Pending JP2025175052A (ja) 2019-10-18 2025-09-05 CAR mRNA送達のための脂質ナノ粒子とその製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025147778A Pending JP2025175052A (ja) 2019-10-18 2025-09-05 CAR mRNA送達のための脂質ナノ粒子とその製剤

Country Status (8)

Country Link
US (1) US20220378700A1 (cg-RX-API-DMAC7.html)
EP (1) EP4045021A4 (cg-RX-API-DMAC7.html)
JP (2) JP7744687B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220084366A (cg-RX-API-DMAC7.html)
CN (1) CN114828837A (cg-RX-API-DMAC7.html)
AU (1) AU2020366519B2 (cg-RX-API-DMAC7.html)
CA (1) CA3155075A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021077067A1 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
US20240298649A1 (en) * 2021-06-14 2024-09-12 Flagship Pioneering Innovations Vi, Llc Modification of plant messenger packs
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
CN115724806B (zh) * 2021-08-25 2025-07-01 广州谷森制药有限公司 阳离子脂质化合物
WO2023044343A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
CA3233490A1 (en) * 2021-09-28 2023-04-06 The Trustees Of The University Of Pennsylvania Compositions and methods for t cell targeted delivery of therapeutic agents
EP4408437A4 (en) * 2021-10-01 2025-08-27 Univ Pennsylvania LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS OF USE THEREOF
US20250043269A1 (en) 2021-11-03 2025-02-06 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Precise Genome Editing Using Retrons
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183300A1 (en) * 2022-03-22 2023-09-28 The Children's Medical Center Corporation Compositions and methods for prevention and treatment of genetic disease
CA3255619A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
EP4519243A4 (en) * 2022-05-04 2026-04-22 Univ Pennsylvania Siloxane-based lipids, lipid nanoparticle compositions comprising them, and their methods of use for targeted administration
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
JP2025525569A (ja) 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド 遺伝子編集成分、システム、及び使用方法
WO2024026029A2 (en) * 2022-07-27 2024-02-01 Trustees Of Tufts College Lipid nanoparticles for immunotherapy
AU2023329392A1 (en) 2022-08-25 2025-02-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
WO2024206230A1 (en) * 2023-03-24 2024-10-03 Trustees Of Tufts College Tissue targeting lipids and lipid nanoparticles
WO2024220609A1 (en) * 2023-04-18 2024-10-24 The Trustees Of The University Of Pennsylvania Ionizable lipid compounds, lipid nanoparticles (lnps) comprising the same, and methods of use thereof for cell engineering
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025008510A1 (en) * 2023-07-06 2025-01-09 Etherna Immunotherapies Nv Ionizable lipids
IT202300015003A1 (it) * 2023-07-18 2025-01-18 Univ Degli Studi Di Salerno Composizione e procedimento per la realizzazione di nano-carriers lipidici ed i relativi nano-carriers lipidici di uso biomedico
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
EP4771154A2 (en) 2023-09-01 2026-07-08 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
EP4784174A1 (en) * 2023-09-28 2026-08-05 Trustees of the University of Pennsylvania Compositions and methods for targeting immune cells
WO2025075396A1 (ko) * 2023-10-06 2025-04-10 한국과학기술연구원 타겟 핵산 검출물질이 담지된 지질 나노입자 및 이를 이용한 막융합 기반의 타겟 핵산 검출 방법
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
IL327927A (en) * 2023-10-22 2026-06-01 Tessera Therapeutics Inc Lipid nanoparticles for delivery of therapeutic payloads to t cells
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
AU2024409393A1 (en) * 2023-12-18 2026-07-09 Nanovation Therapeutics Inc. Lipid nanoparticles having non-polar lipids for nucleic acid delivery to the liver
AU2024409925A1 (en) 2023-12-26 2026-08-06 Emmune, Inc. Systems for nucleic acid transfer
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025184476A1 (en) * 2024-02-29 2025-09-04 The Trustees Of The University Of Pennsylvania Cationic degradable lipid compositions, lipid nanoparticles (lnps) comprising same, and methods of use thereof
WO2025252759A1 (en) 2024-06-03 2025-12-11 Bio-Sourcing Transient expression by lipid nanoparticle formulations
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026015458A1 (en) * 2024-07-08 2026-01-15 Memorial Sloan-Kettering Cancer Center Cells comprising non-hla restricted t cell receptors
WO2026071602A1 (ko) * 2024-09-30 2026-04-02 한국과학기술연구원 면역세포 내 유전자 조작을 위한 신규한 지질나노입자 조성물
WO2026095067A1 (ja) * 2024-11-01 2026-05-07 Agc株式会社 核酸送達用脂質ナノ粒子
WO2026109722A1 (en) 2024-11-21 2026-05-28 Aldexchem Kft. Advanced silicon-containing lipid nanoparticles for efficient human t cell transfection
WO2026122685A1 (en) 2024-12-03 2026-06-11 Orna Therapeutics, Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026161895A1 (en) 2025-01-27 2026-07-30 Tune Therapeutics, Inc. Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression
WO2026165530A1 (en) 2025-02-03 2026-08-06 Renagade Therapeutics Management Inc. Hydrophilic polymer lipids for use in lipid nanoparticles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053572A2 (en) * 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9126966B2 (en) * 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
EP3247328B1 (en) * 2015-01-21 2026-01-07 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
US20190241658A1 (en) * 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
AU2017337073A1 (en) * 2016-09-30 2019-04-18 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
US20190314291A1 (en) * 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells

Similar Documents

Publication Publication Date Title
JP2022552009A5 (cg-RX-API-DMAC7.html)
JP2025175052A5 (cg-RX-API-DMAC7.html)
JP2026012402A5 (cg-RX-API-DMAC7.html)
AU2019345104B2 (en) Therapeutic nanoparticles and methods of use thereof
Dass Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection
RU2175337C2 (ru) Полинуклеотидные композиции
CN101291653B (zh) 脂质包封的干扰rna
JP2021535226A5 (cg-RX-API-DMAC7.html)
JP2012509258A (ja) 核酸送達系のための分岐カチオン性脂質
JP2022552008A (ja) CAR mRNA送達のための脂質ナノ粒子とその製剤
JP2011529912A (ja) 核酸送達システム用のナノ粒子組成物
JP2012509272A (ja) 核酸送達系のための放出性カチオン脂質
CA3198599A1 (en) Tissue-specific nucleic acid delivery by 1,2-dioleoyl-3-trimethylammonium-propane (dotap) lipid nanoparticles
JP2021526505A (ja) 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法
CN120641465A (zh) 新颖的聚甘油缀合脂质和包含其的脂质纳米颗粒组合物
Lee et al. Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor
CN118001254B (zh) 靶向抗原呈递细胞的脂质组合物及其应用
EP4640668A1 (en) Lipid compound, lipid nanoparticle comprising same and use thereof
EP4387657A1 (en) Lipid nanoparticle formulations
CN121816355A (zh) Toll样受体(TLR)激动剂类脂质化合物、包含其的脂质纳米颗粒(LNP)及其使用方法
US20240417738A1 (en) Immunotherapies for the treatment of cancer
JPWO2022244815A5 (cg-RX-API-DMAC7.html)
WO2025090663A1 (en) Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
US12064512B2 (en) Silyl lipids suitable for enhanced delivery of anti-viral therapeutics
JPWO2009153888A1 (ja) 薬物担体